More than appetite support
in 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide medicines
Researchers study Ipamorelin for GH stimulation, appetite signaling, metabolic regulation, and cellular repair
March 5, 2026: FDA Issues Warning Letter to Novo Nordisk About Reporting Adverse Events for its GLP-1s The FDAs Center for Drug Evaluation and Research (CDER) has issued a warning letter to Novo Nordisk, Ozempics maker
While they can provide targeted nutrient support, a healthy diet remains essential for overall well-being
Using a weekly GLP-1 option, like dulaglutide or extended-release exenatide, alongside daily metformin simplifies the routine, making it easier for patients to manage